


Current Speaker: Abby & Ilisha

Unmet Clinical Needs






> 131.5
million people
will suffer with
dementia by
2050


> 99% of AD drugs have been discontinued despite tremendous research and investments

~70% of dementia cases are caused by AD, which results in brain atrophy and death




has proven to have beneficial therapeutic effects on AD patients but requires improvement






Current Speaker: Niharika


Gamma Oscillations








Our Solution








Current Speaker: Gaia

Comparison to Current Technologies


Gamma Oscillation Magnetic Stimulation Cap

- At-Home
- Cost Effective
- Non-invasive
- ✓ Direct Stimulation
- Customizable



DBS Electrodes

- ✓ At-Home
- Cost Effective
- Non-invasive
- ✓ Direct Stimulation
- Customizable



Alzheimer's Drugs

- At-Home
- Cost Effective
- Non-invasive
- □ Direct Stimulation
- **X** Customizable




Current Speaker: Gaia

Comparison of Solution to State of the Art

Gamma Oscillation Magnetic Stimulation Cap

- At-Home
- Cost Effective
- Non-invasive
- ✓ Direct Stimulation
- Customizable



Cognito Therapeutics

- At-Home
- Cost Effective
- Non-invasive
- □ Direct Stimulation
- Customizable



Achilles Heels



H1-Coil for Major Depressive Disorder (MDD)



H7-Coil for Obsessive-Compulsive Disorder (OCD)





H4-Coil for Smoking Cessation



for Major Depressive

Disorder (MDD)




Current Speaker: Gaia


Future Work



Critical Temperature




Critical Magnetic Field



Critical Current Density



Mechanical Testing



Electrical Testing



What standards/regulations will you follow?

Applicable Standards











+A1:2012+A2:2020

ISO 10993-1:2018

IEC 62304:2006

IEC 62366-1:2015







ISO 17.220.01



ASTM F1980





ISO 13485:2016 ISO 14971:2019 ISO 20417:2021

Regulations


21CFR862.1345 21 CFR 898 21 CFR 807.87(e) 21 CFR 809.10 21 CFR 820

Intellectual Property – Cognito Therapeutics






Other Intellectual Property - REMED



Other Intellectual Property



Why choose TMS vs DBS?



Remove Surgical Risk




Reduce Cost




Evidence Backed



Why did you choose magnetic stimulation?



What were our key design considerations?






Who did we contact?

Within Northeastern

- Professor Yaseen (Optical Microscopy and Neural-Imaging)
- Professor Sozer (Biophysics, Electrostimulation)
- Professor Makowski (Biophysical data analysis and AD)
- Professor Barenberg (instructor)


External Sources

- Rick Kuntz (Medtronic, Cognito Board)



Cost And Market

- In the United States, the cost of DBS surgery (including the implanted device, hospital fees and anesthesia) can range from \$35,000 to \$100,000.
- Cognito Therapeutics has raised \$53.3 million in funding.
- Typical TMS caps cost \$20
 with every treatment costing ~\$300



How would you design your animal experiments?

